BRIEF—Spin out formed to advance ProQR's DEB activities

ProQR Therapeutics, a Dutch company developing RNA medicines for severe genetic rare diseases, has spun out its dystrophic epidermolysis bullosa (DEB) activities into the newly-formed company, Wings Therapeutics.

This new company is formed and financed by New York-based EB Research Partnership, the largest global non-profit dedicated to treating and curing epidermolysis bullosa.

Wings will continue conducting a Phase I/II trial for QR-313 in patients that suffer from DEB due to mutations in exon 73. The company will also progress other RNA molecules that are designed for other mutations that cause DEB.

ProQR will hold on to a small stake of Wings and will be eligible for milestone and royalty rights to commercial products. Financial details were not disclosed.